About Melio
Melio is a company based in Santa Clara (United States) founded in 2018 by Shelley Lawrence, Stephanie Fraley, and Mridu Sinha. It operates as a HealthTech. Melio has raised $4.25 million across 3 funding rounds from investors including IndieBio and LongeVC. Melio offers products and services including Melio Diagnostic Platform.
- Headquarter Santa Clara, United States
- Founders Shelley Lawrence, Stephanie Fraley, Mridu Sinha
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Melio, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$4.25 M (USD)
in 3 rounds
-
Latest Funding Round
$4 M (USD), Series A
Jun 28, 2024
-
Investors
IndieBio
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Melio
Melio offers a comprehensive portfolio of products and services, including Melio Diagnostic Platform.
Bloodborne pathogen testing is delivered rapidly and accurately.
People of Melio
Unlock access to complete
Unlock access to complete
Funding Insights of Melio
Melio has successfully raised a total of $4.25M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $4 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $4.0M
-
First Round
First Round
(22 Dec 2022)
- Investors Count 2
Investors in Melio
Melio has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include IndieBio and LongeVC.
Investments & Acquisitions by Melio
Financial Statements - Melio
Melio Comparisons
Competitors of Melio
Latest news on Melio
Frequently Asked Questions about Melio
Melio was founded in 2018 and raised its 1st funding round 4 years after it was founded.
Melio is headquartered in Santa Clara, United States. It is registered at Santa Clara, California, United States.
Mridu Sinha is the current CEO of Melio. They have also founded this company.
Melio is a funded company, having raised a total of $4.25M across 3 funding rounds to date. The company's 1st funding round was a Seed of $250K, raised on Dec 22, 2022.
A culture-free, rapid, and comprehensive blood testing platform is developed by Melio to identify pathogens in hours instead of days. Focus is placed on critical applications such as newborn care in NICUs, where timely diagnosis is essential. Advanced systems engineering, microfluidics, and machine learning are integrated to ensure faster and precise treatments. The technology is designed to adapt and detect newly emerging pathogens, expanding its diagnostic database. Solutions are aimed at addressing global challenges like antibiotic resistance within the healthcare sector.
Melio offers Melio Diagnostic Platform.
Melio has 2 investors. Key investors include IndieBio, and LongeVC.